Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med 2021; published online Sept 1. https://doi.org/10.1016/S2213-2600(21)00331-3—In this Article, in figure 2A the number at risk for the baricitinib group at Day 14 should be 684. This correction has been made to the online version as of Sept 8, 2021 and will be made to the printed version.
. 2021 Sep 8;9(10):e102. doi: 10.1016/S2213-2600(21)00410-0
Correction to Lancet Respir Med 2021; published online Sept 1. https://doi.org/10.1016/S2213-2600(21)00331-3
Issue date 2021 Oct.
© 2021 Elsevier Ltd. All rights reserved.
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
PMCID: PMC8425787 PMID: 34508656